Home / Therapies / Blood Glucose Control (page 2)

Blood Glucose Control

Not All Insulin Resistance Is the Same: Why Fat and Muscle May Matter Differently

Medical illustration comparing tissue-specific insulin resistance in adipose tissue and skeletal muscle and their different responses to insulin.

Insulin resistance is often discussed as though it were one metabolic problem affecting the entire body equally. However, emerging research suggests the picture is more complex. Tissue-specific insulin resistance means that fat, muscle, the liver, and other tissues may not respond to insulin in the same way. More importantly, resistance …

Read More »

Human vs. Analogue Insulin: Does Newer Really Mean Better for Type 1 Diabetes?

Human insulin and analogue insulin options used in Type 1 diabetes treatment

The choice of human vs analogue insulin is especially important for people with Type 1 diabetes who live where healthcare resources are limited. Analogue insulins are often preferred because their action can be more predictable and flexible. However, human insulin is generally less expensive and may be easier for health …

Read More »

When “Type 2” Isn’t Type 2: Clues to Type 3c Diabetes

Pancreas model, glucose meter, and clinical assessment representing type 3c diabetes diagnosis and pancreatogenic diabetes.

A patient develops diabetes in adulthood, so Type 2 diabetes may seem like the obvious diagnosis. However, what if that patient also has chronic pancreatitis, unexplained weight loss, pancreatic surgery, or symptoms of poor nutrient absorption? Those details can change the clinical picture. Careful evaluation can reveal Type 3c diabetes …

Read More »

Which Diabetes Drug Will Work Best? New Research Puts Precision Prescribing to the Test

Precision diabetes treatment concept showing sitagliptin, canagliflozin, and pioglitazone with glucose monitoring and personalized care tools.

Precision diabetes treatment aims to answer a question clinicians and patients face every day: which diabetes drug is most likely to work best for this particular person? A new analysis from the TriMaster crossover trial offers an important clue. Researchers compared several precision-medicine strategies for predicting responses to sitagliptin, canagliflozin, …

Read More »

Why Does Eating Less Improve Insulin Sensitivity? Ceramides May Hold Part of the Answer

Healthy meal illustrating how calorie restriction may affect ceramides, adiponectin, and insulin sensitivity.

Why does eating less sometimes improve insulin sensitivity beyond what we might expect from weight loss alone? Human research points to an intriguing connection between ceramides, insulin resistance, and adiponectin. Findings from the CALERIE research program suggest that sustained, moderate calorie restriction changes circulating bioactive lipids in ways that may …

Read More »

Diagnosed Younger: Does Type 1 Onset Shape Later Risk?

Child, teenager, and adult with type 1 diabetes illustrating how age at onset may relate to long-term complication risks.

Does being diagnosed with type 1 diabetes at age 6 carry the same long-term risks as being diagnosed at 16? Researchers have been asking that question for years. Increasingly, evidence suggests that age at type 1 diabetes onset may help explain differences in complication patterns later in life. However, age …

Read More »

Beyond A1C: Can CGM Help Prevent Severe Hypoglycemia and DKA?

Person using a continuous glucose monitor to track glucose levels and help prevent severe hypoglycemia and DKA.

Continuous glucose monitoring has changed how clinicians and people with diabetes think about glucose control. Yet the next question is more important than whether CGM improves A1C or Time in Range. Can it prevent events that send patients to the emergency department or hospital? Growing evidence suggests that CGM may …

Read More »

Beyond hs-CRP: Could suPAR Reveal Hidden Heart Risk in Type 2 Diabetes?

suPAR biomarker blood test with heart model and glucose meter representing cardiovascular risk in type 2 diabetes

People with type 2 diabetes can face substantial cardiovascular risk even when clinicians address familiar risk factors such as LDL cholesterol, blood pressure, smoking, and blood glucose. Could another blood marker help reveal some of the risk that remains? Emerging research on the suPAR biomarker in diabetes suggests it may …

Read More »

Can Weight Loss Delay Type 1 Diabetes? What the Pre-Symptomatic Data Really Show

Healthy food, exercise shoes, glucose meter, scale, and pancreas illustration representing weight and type 1 diabetes prevention research.

Efforts to prevent or delay type 1 diabetes have traditionally focused on the autoimmune attack that destroys insulin-producing beta cells. However, emerging research suggests metabolic stress may also influence how quickly vulnerable people progress to clinical disease. A 2026 TrialNet analysis found that autoantibody-positive people with overweight or obesity who …

Read More »

A Type 1 Breakthrough: Can We Transplant Islets With Less Toxic Immunosuppression?

Medical illustration of transplanted pancreatic islet cells protected from immune attack during experimental type 1 diabetes treatment.

Donor islet transplantation has long offered an intriguing possibility for people with severe type 1 diabetes: restore the body’s ability to make insulin instead of only replacing insulin from the outside. However, there has always been a major tradeoff. Patients need powerful immunosuppressive drugs to keep transplanted cells alive, and …

Read More »